On May 15th, this website posted information about a Phase 1-2 clinical trial sponsored by the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The proposed therapeutic regimen initially consisted of the NCI vaccine Prostvac, and two antibodies, ipilimumab (Yervoy®) and nivolumab (Opdivo®). However, toxic events recently surfaced in the use of ipilimumab in several patients necessitating its removal from this particular NCI trial. In addition, a website post dated April 11th, 2017 cited the lack of activity of ipilimumab as a sole agent in prostate cancer clinical trials. However, it was proposed that ipilimumab might be more useful in combination immunotherapy.